Canandaigua National Trust Co of Florida Acquires 16,555 Shares of Eli Lilly and Company $LLY

Canandaigua National Trust Co of Florida bought a new position in shares of Eli Lilly and Company (NYSE:LLY) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 16,555 shares of the company’s stock, valued at approximately $19,155,000. Eli Lilly and Company comprises approximately 10.8% of Canandaigua National Trust Co of Florida’s holdings, making the stock its biggest holding.

Other hedge funds and other institutional investors have also modified their holdings of the company. Osbon Capital Management LLC acquired a new stake in Eli Lilly and Company during the fourth quarter worth approximately $25,000. Basso Capital Management L.P. acquired a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $30,000. Maseco LLP grew its position in shares of Eli Lilly and Company by 466.7% in the first quarter. Maseco LLP now owns 34 shares of the company’s stock valued at $31,000 after purchasing an additional 28 shares during the last quarter. Aventus Investment Advisors Inc. increased its stake in shares of Eli Lilly and Company by 270.0% during the first quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company’s stock worth $34,000 after purchasing an additional 27 shares during the period. Finally, Marshall & Sterling Wealth Advisors Inc. lifted its holdings in Eli Lilly and Company by 60.0% during the 1st quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock worth $37,000 after purchasing an additional 15 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

LLY stock traded up $29.46 during midday trading on Wednesday, reaching $1,186.95. The company had a trading volume of 2,300,611 shares, compared to its average volume of 2,974,313. Eli Lilly and Company has a 1-year low of $783.85 and a 1-year high of $1,292.65. The stock has a 50 day moving average price of $1,173.98 and a 200-day moving average price of $1,092.69. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The company has a market capitalization of $1.12 trillion, a price-to-earnings ratio of 39.83, a price-to-earnings-growth ratio of 1.40 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. During the same period last year, the firm earned $6.31 EPS. The business’s quarterly revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities research analysts expect that Eli Lilly and Company will post 36.66 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have commented on LLY shares. Citigroup upped their price objective on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Wells Fargo & Company boosted their target price on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Jefferies Financial Group upped their price target on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a research note on Tuesday, June 9th. The Goldman Sachs Group lifted their price objective on shares of Eli Lilly and Company from $1,367.00 to $1,371.00 and gave the stock a “buy” rating in a research note on Thursday, September 17th. Finally, Berenberg Bank set a $1,400.00 price objective on shares of Eli Lilly and Company and gave the company a “buy” rating in a report on Tuesday, September 15th. One analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $1,312.36.

Insider Buying and Selling at Eli Lilly and Company

In other news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the transaction, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the business’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares of the company’s stock, valued at $63,628,139.70. This trade represents a 10.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,500 shares of company stock worth $15,958,170 over the last three months. Corporate insiders own 0.14% of the company’s stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Healthcare was one of the market’s few strong sectors, with Eli Lilly among the leaders. The relative strength likely reflects continued investor preference for defensive healthcare companies and Lilly’s strong growth profile. Moderna, Eli Lilly Lead Healthcare Stocks Higher on a Down Day for Markets
• Positive Sentiment: Analysts and commentators highlighted growth opportunities beyond Mounjaro and Zepbound, including oncology, immunology, neuroscience, insulin and other pipeline programs. This supports the view that Lilly’s long-term outlook is not dependent on a single obesity-drug franchise. Where Will Eli Lilly Stock Be in 5 Years? Follow the Pipeline Beyond Zepbound
• Positive Sentiment: Recent data for Lilly’s oral GLP-1 candidate Foundayo reportedly showed greater weight loss and better blood-sugar control than oral semaglutide in adults with type 2 diabetes. A successful oral product could broaden access and add another major growth driver, though the analysis still requires further validation. Foundayo Showed Better Results Than Oral Semaglutide in a New Analysis
• Positive Sentiment: Retatrutide, Lilly’s next-generation triple-hormone obesity candidate, was identified as a potentially underappreciated catalyst. Reported trial weight loss has exceeded Zepbound’s results, and a regulatory filing is expected in early 2027. Eli Lilly’s New Drug Data Sets Up a High-Stakes 2026
• Neutral Sentiment: Investment commentary remains divided: Lilly’s rapid revenue and earnings growth support premium valuation, but the stock trades near 40 times trailing earnings, leaving limited room for execution errors. Eli Lilly: Impressive Growth, Questionable Valuation
• Negative Sentiment: The World Health Organization’s new childhood-obesity guidelines could increase scrutiny of obesity-drug use in younger patients and create additional regulatory or adoption hurdles for Lilly and Novo Nordisk. Eli Lilly and Novo Face New Pressure from WHO’s Childhood Obesity Guidelines

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.